Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Model
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The aim of this study is to investigate whether ANEB-001 effectively penetrates the brain and
inhibits the psychotropic effects of Δ9-Tetrahydrocannabinol (THC), the main psychoactive
constituent of cannabis. This randomized, placebo-controlled, double-blind study is designed
as a proof-of-pharmacology and dose finding study for the antagonistic effect of ANEB-001
during a THC challenge. Results of this study will inform the future potential use of
ANEB-001 as an emergency treatment for THC intoxication.